Published in J Exp Med on December 01, 1971
Complement and meningococcal infection. Br Med J (1976) 2.28
Acute inflammation. A review. Am J Pathol (1977) 2.06
The glomerular mesangium. 3. Acute immune mesangial injury: a new model of glomerulonephritis. J Exp Med (1973) 1.40
Complement activation in children with acute malaria. Clin Exp Immunol (1974) 1.37
The human complement system in thrombin-mediated platelet function. J Exp Med (1978) 1.36
Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest (1983) 1.33
Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. J Clin Invest (1974) 1.20
Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation. J Clin Invest (1973) 1.14
Analysis of bypass activation of C3 by endotoxic LPS and loss of this potency. Immunology (1973) 1.13
Activation of the alternate complement pathway by autologous red cell stroma. J Exp Med (1973) 1.13
Cryoglobulins, circulating immune complexes, and complement activation in cerebral malaria. Infect Immun (1981) 1.12
Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury. J Exp Med (1975) 1.04
Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol (1974) 1.04
Abnormal platelet function in C3-deficient mice. J Thromb Haemost (2009) 0.96
Evidence for complement-induced endothelial injury in vivo: a comparative ultrastructural tracer study in a controlled model of hyperacute rat cardiac allograft rejection. Am J Pathol (1982) 0.95
Maturation of the human complement system. I. Onset time and sites of fetal C1q, C4, C3, and C5 synthesis. J Clin Invest (1973) 0.94
Bacteroidaceae in thromboembolic disease: effects of cell wall components on blood coagulation in vivo and in vitro. Infect Immun (1973) 0.94
Effects of intravascular clotting on the activation of the complement system: The role of the platelet. Am J Pathol (1975) 0.92
Effect of pneumococci on blood clotting, platelets, and polymorphonuclear leukocytes. Infect Immun (1975) 0.89
Humoral immunostimulation. IV. Role of complement. J Exp Med (1975) 0.88
Complement-dependent platelet injury by staphylococcal protein A. J Exp Med (1972) 0.87
Pathogenetic mechanisms in dengue haemorrhagic fever: report of an international collaborative study. Bull World Health Organ (1973) 0.83
The platelet as an inflammatory cell. Trans Am Clin Climatol Assoc (1979) 0.78
Potentiation of endotoxin-induced consumptive coagulopathy by lead acetate administration. Infect Immun (1974) 0.78
Intraglomerular deposition of fibrin/fibrinogen-related antigen in children with various renal diseases. Am J Pathol (1988) 0.75
Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis. Br Med J (1975) 0.75
Formation of slow-reacting substance by guinea pig immunoglobulins. Am J Pathol (1976) 0.75
The role of complement in localized shwartzman reaction: studies with congenitally C6-deficient rabbits. Clin Exp Immunol (1974) 0.75
Immunofluorescent localization of immunoglobulins, complement, and fibrinogen in human diseases. I. Systemic lupus erythematosus. J Clin Invest (1965) 4.55
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
THE SHWARTZMAN REACTION: PATHOGENETIC MECHANISMS AND CLINICAL MANIFESTATIONS. Annu Rev Med (1965) 3.02
The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins. J Immunol (1970) 2.70
An immunofluorescent study of pathogenic mechanisms in glomerular diseases. N Engl J Med (1966) 2.70
An effect of antigen-antibody interaction on blood coagulation. J Exp Med (1959) 2.43
Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol (1969) 2.25
Effects of bacterial endotoxin on rabbit platelets. II. Enhancement of platelet factor 3 activity in vitro and in vivo. J Exp Med (1962) 2.01
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
The biologic activities of guinea pig antibodies. I. Separation of gamma1 and gamma2 immunoglobulins and their participation in allergic reactions of the immediate type. J Immunol (1970) 1.85
Activation of Hageman factor by ellagic acid and the generalized Shwartzman reaction. Am J Pathol (1969) 1.20
Endotoxin-induced kinin (bradykinin) formation: activation of Hageman factor and plasma kallikrein in human plasma. Life Sci (1970) 0.95
F. The relation of complement to other systems. Proc R Soc Lond B Biol Sci (1969) 0.89
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Complement. Annu Rev Biochem (1975) 6.00
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest (1980) 2.88
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
The complex multimeric composition of factor VIII/von Willebrand factor. Blood (1981) 2.76
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med (1969) 2.25
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Cytotoxic effects of leukocyres triggered by complement bound to target cells. Science (1969) 2.15
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Complement: substitution of the terminal component in immune hemolysis by 1,10-phenanthroline. Science (1967) 2.11
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
The ninth component of human complement: purification and physicochemical characterization. J Immunol (1980) 2.09
Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest (1977) 2.07
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
C1q protein of human complement. Biochemistry (1972) 2.06
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8). J Exp Med (1976) 1.90
The alternative pathway of complement activation. Adv Immunol (1976) 1.87
Mechanism of action of factor D of the alternative complement pathway. J Exp Med (1978) 1.87
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
von Willebrand factor and von Willebrand disease. Blood (1987) 1.83
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol (1978) 1.81
Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults. J Immunol (1967) 1.79
Physico-chemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes. Immunology (1967) 1.79
Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci U S A (1979) 1.76
Immunofluorescent localization of the third and the fourth component of complement in synovial tissue from patients with rheumatoid arthritis. J Lab Clin Med (1967) 1.76
Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol (1978) 1.76
von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem (1986) 1.71
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 1.71
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67
Complement-immunoglobulin relation: deficiency of C'1q associated with impaired immunoglobulin G synthesis. Science (1969) 1.67
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods (1984) 1.65
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
A fragment of the third component of human complement with anaphylatoxin activity. Biochemistry (1971) 1.64
A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med (1974) 1.63
Pore-forming peptide of pathogenic Entamoeba histolytica. Proc Natl Acad Sci U S A (1991) 1.63
Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor 8(). J Clin Invest (1971) 1.61
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med (1979) 1.55
Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med (1975) 1.54
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell (1985) 1.51